Egenix obtained rights to inhibitors of translation initiation, while Millennium is focused on work related to protein homeostasis.
Harvard Medical School granted Egenix rights to discoveries related to cancer drug development as well as inked a license and research agreement with Millenium Pharmaceuticals’ focused on protein homeostasis.
Egenix’ licensed technologies comprise small molecule inhibitors of translation initiation and the use of translation initiation-specific biomarkers to assess tumor sensitivity to anticancer therapy.
The licensed inhibitors of translation initiation target the eIF4F and ternary complexes, two regulators of mRNA translation into protein. Egenix believes that small molecules for the inhibition of translation initiation are at the forefront of modern cancer therapeutics currently under development and that this platform has the potential.
Separately, Millennium Pharmaceuticals’ licensed protein homeostasis research from Harvard Medical School. The parties will jointly advance the program under a sponsored research agreement.
Studies have shown various pathways that regulate cellular protein homeostasis are linked to the pathologic properties of a broad range of cancers, the collaborators remark. The initial research-based agreement is focused on advancing knowledge in this evolving field over the course of three years.